You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
陽普醫療(300030.SZ):公司正在研發基於AI的全自動血栓彈力圖系統項目以及分子診斷採血管建設項目
格隆匯 07-24 18:18

格隆匯7月24日丨有投資者向陽普醫療(300030.SZ)提問:公司的研發投入情況如何?有什麼研發成果?

陽普醫療回覆:公司重視研發,持續推進技術創新。2022年,公司研發投入佔營業收入比例為6.14%,相比上年同期上升0.61個百分點。同時,公司以自主研發創新為基礎,研發團隊多數為擁有生物化學、臨牀醫學等領域的專業人士。2022年,公司及子公司新獲專利授權24項,其中國內發明專利3項、實用新型20項、外觀設計1項;新增國內商標註冊證7件;新增軟件著作權28項。目前,公司正在研發基於AI的全自動血栓彈力圖系統項目以及分子診斷採血管建設項目。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account